Recommendation of the President – Alecensa (alectinib)

On 13 January 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 2/2025 on the appraisal Alecensa (alectinib) under the drug program “Treatment of patients with lung cancer (ICD-10 C34) and pleural mesothelioma (ICD-10 C45)”

Publication in Public Information Bulletin (BIP) >>